Regado Biosciences Inc (RGDO) 6.30 $RGDO
Regado Biosciences Announces Closing of Public Offering of Common Stock
PR Newswire - Wed Apr 16, 8:35AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previously announced underwritten public offering. The gross proceeds to Regado from its sale of 10,000,000 shares of common stock at a price to the public of $6.00 per share were approximately $60.0 million, prior to deducting underwriting discounts and commissions and other offering expenses payable by Regado.
This Week's 5 Dumbest Stock Moves
Rick Munarriz, The Motley Fool - Motley Fool - Fri Apr 11, 3:45PM CDT
Stupidity is contagious -- even respectable companies can catch it. As we do every week, let's take a look at five dumb financial events this week that may make your head spin. 1. Dis a Pier Sometimes it's hard to herd scapegoats. Pier 1...
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Why Regado Biosciences (RGDO) Stock Is Down Today
at The Street - Fri Apr 11, 9:37AM CDT
Regado Biosciences (RGDO) plunged on Friday after the biopharmaceutical company priced an offering of its common stock. The company priced 10 million shares at $6 a share. The offering should close on or about April 16 and includes a 30-day option...
Regado Biosciences Announces Pricing of Public Offering of Common Stock
PR Newswire - Fri Apr 11, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $6.00 per share to the public. The gross proceeds to Regado from this offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Regado. The offering is expected to close on or about April 16, 2014, subject to the satisfaction of customary closing conditions. Regado has granted the underwriters a 30-day option to purchase up to an aggregate of 1,500,000 additional shares of common stock. Regado expects to use the net proceeds of this offering to fund further clinical development of its lead product candidate, REG1, and for working capital and other general corporate purposes.
Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1
PR Newswire - Wed Apr 02, 8:20PM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care cardiovascular indications, today announced that after achieving the 1,000-patient enrollment milestone, enrollment in the REGULATE-PCI trial has been extended to non ST-elevated myocardial infarction (N-STEMI) patients to include the planned "all comers" percutaneous coronary intervention (PCI) patient population described in the trial protocol. REGULATE-PCI is Regado's Phase 3 trial comparing REG1 to bivalirudin for superiority in reducing ischemic events in patients undergoing PCI, excluding those with ST-elevated myocardial infarction (STEMI). This development program was recently granted Fast Track designation by the FDA.
Regado Biosciences to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
PR Newswire - Thu Mar 20, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will present at the 21st Annual Future Leaders in the Biotech Industry Conference taking place on March 28, 2014, at the Millennium Broadway Hotel & Conference Center in New York City.
Regado Biosciences Announces Year-End 2013 Financial Results and Corporate Highlights
PR Newswire - Wed Mar 12, 4:35PM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced its year-end 2013 corporate highlights and financial results. A conference call and webcast to discuss the results will be held March 13 at 8:30 a.m. EDT.
Regado Rises on REG1 Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 1:16PM CDT
Shares of Regado soared 38.1% and also touched a 52-week high.
3 Stocks Making Health-Care Investors Big Money Today
David Williamson, The Motley Fool - Motley Fool - Mon Mar 10, 5:57PM CDT
Despite an overall down day on the market today, the health-care sector emerged looking pretty good, with a handful of big winners. In this video, Motley Fool health-care analyst David Williamson looks at three top performers. Regado Biosciences ...
FDA Designates Regado's REG1 in PCI as a Fast Track Development Program
PR Newswire - Mon Mar 10, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration (FDA) has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program. The FDA's Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions that fill an unmet medical need, with the overall goal of getting new drugs to patients earlier.
Regado Biosciences to Provide Year-End and Fourth Quarter 2013 Financial Results
PR Newswire - Thu Mar 06, 6:30AM CST
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will hold a conference call and live audio webcast on Thursday, March 13, at 8:30 a.m. EDT to discuss its year-end and fourth quarter 2013 financial results.
Regado Biosciences to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 6:30AM CST
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will present at the 26th Annual ROTH Conference taking place March 9-12, 2014, at The Ritz-Carlton, Laguna Niguel, in Dana Point, Calif.
The Global Aptamers Market was Valued at $287 Million in 2013 and is Expected to Reach $2.1 Billion by 2018
M2 - Wed Feb 26, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/zm94cc/aptamers_market) has announced the addition of the "Aptamers Market Technology Trend Analysis - Global Forecasts to 2018" report to their offering. The global aptamers market is anticipated to reach $2.1 billion by 2018 growing at a CAGR of 49.24%. The aptamers market is divided by geography (North America, Europe, Asia-Pacific and Rest of the World), application segments (therapeutics, diagnostics, biosensors, drug discovery, biomarker discovery, and research applications) and aptamer type (Nucleic acid aptamers and Peptide aptamers). Further each application segment and the aptamer type is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned application segments, research applications is the largest revenue segment; however, biomarker discovery and diagnostics will be the fastest-growing segment. The potential growth of the market is attributed to future diagnostics, drug discovery and research applications. The future approval of a few diagnostic tests specifically for infectious diseases and a couple of drugs in the market will greatly propel the market. The global market for aptamers is expected to grow, backed by technological advancements with respect to selection processes and synthesis. The market will experience continuous improvements in aptamer synthesis and its applicability in drug discovery and routine research. The market is witnessing a trend toward development of personalized medicine and point-of-care diagnostic tests. Additionally, the demand for safe and cost-effective drugs for treatment of cancer (which can be fulfilled by aptamer therapeutics), will remarkably fuel market growth. Companies Mentioned: - AM Biotechnologies, Llc - Aptagen, LIC - Aptamatrix, Inc - Aptamer Sciences Inc - Aptamer Solutions Ltd - Aptares AG - Aptusbiotech - Base Pair Biotechnologies - Bioapter SL - Cd Genomics - Integrated Dna Technologies, Inc - Lucerna, Inc - NOXXON Pharma AG - Neoventures Biotechnology Inc - OTC Biotech - Ophthotech Corporation - Pfizer - Regado Biosciences, Inc - Somalogic, Inc - Trilink Biotechnologies, Inc - Vivonics For more information visit http://www.researchandmarkets.com/research/zm...ers_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Regado Biosciences Announces Closing of Public Offering of Common Stock
PR Newswire - Wed Apr 16, 8:35AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previously announced underwritten public offering. The gross proceeds to Regado from its sale of 10,000,000 shares of common stock at a price to the public of $6.00 per share were approximately $60.0 million, prior to deducting underwriting discounts and commissions and other offering expenses payable by Regado.
This Week's 5 Dumbest Stock Moves
Rick Munarriz, The Motley Fool - Motley Fool - Fri Apr 11, 3:45PM CDT
Stupidity is contagious -- even respectable companies can catch it. As we do every week, let's take a look at five dumb financial events this week that may make your head spin. 1. Dis a Pier Sometimes it's hard to herd scapegoats. Pier 1...
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 11, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Why Regado Biosciences (RGDO) Stock Is Down Today
at The Street - Fri Apr 11, 9:37AM CDT
Regado Biosciences (RGDO) plunged on Friday after the biopharmaceutical company priced an offering of its common stock. The company priced 10 million shares at $6 a share. The offering should close on or about April 16 and includes a 30-day option...
Regado Biosciences Announces Pricing of Public Offering of Common Stock
PR Newswire - Fri Apr 11, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $6.00 per share to the public. The gross proceeds to Regado from this offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Regado. The offering is expected to close on or about April 16, 2014, subject to the satisfaction of customary closing conditions. Regado has granted the underwriters a 30-day option to purchase up to an aggregate of 1,500,000 additional shares of common stock. Regado expects to use the net proceeds of this offering to fund further clinical development of its lead product candidate, REG1, and for working capital and other general corporate purposes.
Regado Achieves 1,000-Patient Milestone in Phase 3 Trial of REG1
PR Newswire - Wed Apr 02, 8:20PM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company leading the development of actively controllable therapeutics for acute care cardiovascular indications, today announced that after achieving the 1,000-patient enrollment milestone, enrollment in the REGULATE-PCI trial has been extended to non ST-elevated myocardial infarction (N-STEMI) patients to include the planned "all comers" percutaneous coronary intervention (PCI) patient population described in the trial protocol. REGULATE-PCI is Regado's Phase 3 trial comparing REG1 to bivalirudin for superiority in reducing ischemic events in patients undergoing PCI, excluding those with ST-elevated myocardial infarction (STEMI). This development program was recently granted Fast Track designation by the FDA.
Regado Biosciences to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
PR Newswire - Thu Mar 20, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will present at the 21st Annual Future Leaders in the Biotech Industry Conference taking place on March 28, 2014, at the Millennium Broadway Hotel & Conference Center in New York City.
Regado Biosciences Announces Year-End 2013 Financial Results and Corporate Highlights
PR Newswire - Wed Mar 12, 4:35PM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced its year-end 2013 corporate highlights and financial results. A conference call and webcast to discuss the results will be held March 13 at 8:30 a.m. EDT.
Regado Rises on REG1 Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 1:16PM CDT
Shares of Regado soared 38.1% and also touched a 52-week high.
3 Stocks Making Health-Care Investors Big Money Today
David Williamson, The Motley Fool - Motley Fool - Mon Mar 10, 5:57PM CDT
Despite an overall down day on the market today, the health-care sector emerged looking pretty good, with a handful of big winners. In this video, Motley Fool health-care analyst David Williamson looks at three top performers. Regado Biosciences ...
FDA Designates Regado's REG1 in PCI as a Fast Track Development Program
PR Newswire - Mon Mar 10, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration (FDA) has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program. The FDA's Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions that fill an unmet medical need, with the overall goal of getting new drugs to patients earlier.
Regado Biosciences to Provide Year-End and Fourth Quarter 2013 Financial Results
PR Newswire - Thu Mar 06, 6:30AM CST
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will hold a conference call and live audio webcast on Thursday, March 13, at 8:30 a.m. EDT to discuss its year-end and fourth quarter 2013 financial results.
Regado Biosciences to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 6:30AM CST
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will present at the 26th Annual ROTH Conference taking place March 9-12, 2014, at The Ritz-Carlton, Laguna Niguel, in Dana Point, Calif.
The Global Aptamers Market was Valued at $287 Million in 2013 and is Expected to Reach $2.1 Billion by 2018
M2 - Wed Feb 26, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/zm94cc/aptamers_market) has announced the addition of the "Aptamers Market Technology Trend Analysis - Global Forecasts to 2018" report to their offering. The global aptamers market is anticipated to reach $2.1 billion by 2018 growing at a CAGR of 49.24%. The aptamers market is divided by geography (North America, Europe, Asia-Pacific and Rest of the World), application segments (therapeutics, diagnostics, biosensors, drug discovery, biomarker discovery, and research applications) and aptamer type (Nucleic acid aptamers and Peptide aptamers). Further each application segment and the aptamer type is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned application segments, research applications is the largest revenue segment; however, biomarker discovery and diagnostics will be the fastest-growing segment. The potential growth of the market is attributed to future diagnostics, drug discovery and research applications. The future approval of a few diagnostic tests specifically for infectious diseases and a couple of drugs in the market will greatly propel the market. The global market for aptamers is expected to grow, backed by technological advancements with respect to selection processes and synthesis. The market will experience continuous improvements in aptamer synthesis and its applicability in drug discovery and routine research. The market is witnessing a trend toward development of personalized medicine and point-of-care diagnostic tests. Additionally, the demand for safe and cost-effective drugs for treatment of cancer (which can be fulfilled by aptamer therapeutics), will remarkably fuel market growth. Companies Mentioned: - AM Biotechnologies, Llc - Aptagen, LIC - Aptamatrix, Inc - Aptamer Sciences Inc - Aptamer Solutions Ltd - Aptares AG - Aptusbiotech - Base Pair Biotechnologies - Bioapter SL - Cd Genomics - Integrated Dna Technologies, Inc - Lucerna, Inc - NOXXON Pharma AG - Neoventures Biotechnology Inc - OTC Biotech - Ophthotech Corporation - Pfizer - Regado Biosciences, Inc - Somalogic, Inc - Trilink Biotechnologies, Inc - Vivonics For more information visit http://www.researchandmarkets.com/research/zm...ers_market About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
